2021 Partners
PRA Health Sciences are a full service global contract research organization providing a broad range of product development and data solution services to pharmaceutical and biotechnology companies around the world. Our global operations span more than 90 offices across North America, Europe, Asia, Latin America, South Africa, Australia, and the Middle East.
Learn More
S3 Connected Health partner with pharma to create and operate digital health solutions that improve the lives of people with chronic conditions.
They specialize in cloud-based digital therapeutics and digital therapy management solutions that provide real-world evidence to support access, reimbursement, and value-based care.
Using experience mapping and behavioral science techniques to fully understand the needs of patients, clinicians, payors, and providers, they create custom solutions that improve outcomes.
For over 18 years’, in over 50 countries, across 20 therapy areas, S3 Connected Health have delivered award-winning solutions that are scalable, secure, and regulatory compliant.
We created the Novartis Biome as a bridge to help our partners become an extension of our own teams, working with us as easily and productively as possible to jointly innovate and co-develop digital solutions at scale.
We’re taking on some of the biggest healthcare challenges – something we can’t and don’t want to do on our own. We’re committed to partnering with the best in the ecosystem to combine our deep scientific experience with the expertise of the tech world to develop – and crucially – scale digital solutions that improve and extend patients’ lives.
To do this, we realize we need to make it easier for companies big and small to partner with us. The healthcare industry is notoriously complicated – highly regulated and traditionally behind the curve in terms of digital disruption.
We set our sight on a simple, but powerful vision to advance life science services toward a healthier world.
The journey began when Water Street Healthcare Partners and JLL Partners joined forces to acquire and combine the most comprehensive platform of life sciences services in the industry. Together, we are EVERSANA.
We offer more than 500 clients – from start-ups to established global pharmaceutical leaders – the services they need to bring critical therapies to market while improving the lives of patients around the world.
Learn More
JAZZ Venture Partners invests in companies that extend the boundaries of human performance — improving how we live, learn, work, play, and experience the world.
We seek breakthroughs at the intersection of digital technology and neuroscience that are influencing the human experience, such as augmented reality, artificial intelligence, immersive gaming, and closed-loop human-computer systems.
Our portfolio companies are unlocking human potential in health, mind-body wellness, accelerated learning and training, sports, entertainment, and the enterprise.
Learn More
At our core is perseverance, a fierce determination to overcome any obstacle regardless of setbacks, on behalf of patients and their loved ones. We place greater value on what we can achieve together than on what we can do alone because the needs of those we serve always come first. We will not be bound by doing what’s been done before. Instead, we free ourselves from preconceived notions to discover solutions that advance patient care. Our mission is clear: Otsuka-people, creating new products for better health worldwide.
Learn More
The agenda is purposely built to provide an engaging and interactive learning experience. integrated polls, topic-focused roundtables, Q&A with speakers, “Open-Mic” discussions, and more, you will be able to accelerate your knowledge of Digital Therapeutics as they continue their meteoric rise. The ability to actively or passively be involved in these learning opportunities is yours!
Learn from the experts who are paving the way for digital therapeutics in Europe. Join leading DTx companies, Pharma, Investors, Payers, Clinicians, Governmental Bodies, Patients and more in our senior level audience and leading speaker faculty
The Digital Platform lets you create your own personal agenda. You can attend live sessions, watch on-demand content, take part in open networking sessions, or take a break whenever suits you. Seamlessly hop between learning and networking at any time. Look through the program and slot sessions directly into your calendar, to help fit the conference around the day job. All of this from the comfort of your own home.
“I found this conference eye-opening and had many interesting conversations. I am blown away by the Digital Therapeutics community and its commitment to value-based care”
“DTx is the must attend event in our industry”
“The DTx Series is a fantastic set of meetings. The quality of the investors, entrepreneurs and companies never fails to impress me, and I always leave having learned a lot”
“The conference was tangible, specific and open. I have never been to a conference of this size with such richness of discussion”
“Thanks for catalyzing the industry forward in this emerging field. Looking forward to the next one”
“DTx is an inclusive event, where the participants truly believe that the rising tide will raise all boats”
2021 Speaker Faculty
Anand is a respected global digital health leader—most known for his insights on and experience with technology, strategy and regulatory policy. Anand has been instrumental in WellDoc’s success and the development of BlueStar®. Since joining WellDoc in 2008, he has held core leadership positions that included Chief Data Science Officer, President and Chief Operations Officer. He holds an MS and a PhD in electrical and computer engineering, and an MBA from Carnegie Mellon University.
Jessica is Head of Digital Therapeutics at Vicore Pharma in Sweden. Previously she led the European Policy work for the Digital Therapeutics Alliance and managed clinical projects for respiratory disease at Bellvitge Hospital in Barcelona. With 20 years’ experience in digital health – from developing virtual surgery devices to integrating digital health frameworks at the WHO at national level – she is now focused on developing digital therapeutics products and on the weekends, finishing a PhD in BioMedicine
Kim Baden-Kristensen is the CEO and Co-founder of Brain+, an award winning Danish health tech company specializing in digital therapeutics for neurorehabilitation of disorders and injuries to the Central Nervous System (CNS).
Kim is intensively engaged in digital health care policy debates and initiatives on the European level. He is a founding member of the Digital Therapeutics Partnership, a global non-for-profit with a mission to enhance patient outcomes and quality of care with clinically-validated digital therapeutics.
Kim is an expert within digital therapeutics, with particularly emphasis on neurogame-based rehabilitation and gamified behavioral therapy.
Kim holds an MSc. In Innovation Management from Copenhagen Business School, a Health Care Innovation Management degree from Harvard Business School, and a minor in Cognitive Neuroscience from Copenhagen University.
As Vice President of Marketing & Commercial Development at S3 Connected Health, Matt consults with life science companies on the development and execution of digital therapeutics and digital health solutions.
With over 20 years’ experience of bringing solutions to market for companies including P&G, GSK, and ResMed, Matt has a wealth of experience delivering solutions that capture RWD and RWE to help transform healthcare delivery and improve patient outcomes.
Matt’s current role involves the roll-out of patient and clinician focused digital health solutions across APAC, Latin America, and the US, resolving regulatory challenges and scaling across globally diverse regions.
Francesca Domenech Wuttke, Ph.D. is the Chief Digital Officer of Almirall where she is developing and executing an end-to-end companywide digital transformation. She is responsible for finding use cases across R&D, commercial, manufacturing, finance, legal and HR to apply digital solutions and services to bring efficiencies in terms of time and cost and to open up new business channels for Almirall.
Dr. Wuttke brings with her broad drug development and healthcare expertise in both the US and Europe, with over 20 years of clinical, commercial, strategic and transactional experience. She has worked with diverse organizations including start-ups, consulting, large and specialty pharma as well as academia.
Most recently, she led European investments as Managing Director for the MSD Global Health Innovation Fund, LLC. Previously Dr. Wuttke led Almirall´s Corporate Development Strategy team to transact on both med device and pharma M&A opportunities with a new and targeted focus for the company. Before that Dr. Wuttke worked at Novartis where she was responsible for two Cell and Gene therapy opportunities that were successfully brought into the organisation as well as managing the strategy and commercialisation for the existing portfolio of cell therapy assets.
Dr. Wuttke holds a Ph.D. in Pharmacology from Weill Cornell Graduate School of Medical Sciences and a BA from Cornell University College of Arts and Sciences.
Jean joined Novartis in October 2020 and is responsible for the German branch of Biome. Biome is a global network of innovation hubs, connecting Novartis with the tech ecosystem and leveraging open innovation. Jean holds degrees in Health Economics and Health Policy awarded by the University of Cologne and the London School of Economics. Before working for Novartis, Jean was the Director of Health Insurance at the IGES Institute executing numerous projects for the German statutory insurance system.
Dr. Dixit is a Physician Executive with more than 20 years of experience in the healthcare and life sciences industry. She has been in executive leadership at Sanofi, Allergan, and GE and has been responsible for launching a number of innovative medicines. She was voted innovator of the year at GE in 2008, nominated as a Top 50 Thought Leader in “Big Data” in Life Sciences in 2016, and featured in the Pharma Executive Magazine cover-page article “Real-World Evidence: From Volume to Value” (Oct 13, 2016). Shailja has built and has had successful exits with many projects.
Enrique Estrada is the Director of Business Development at PRA Health Sciences, and has over 25+ years in technology, product management, telecommunications, and digital health experience. He has worked in many transformational roles, including startups and fortune 500 companies where he’s been principal innovator and product owner of new and disruptive technologies and services. Over his career, he’s lead productization efforts for network management tools, telemedicine solutions, unified communications, healthcare exchanges, and patient engagement platforms.
Enrique is passionate about the intersection of technology, business process and healthcare delivery, and focuses on where each piece can play a vital role in delivering solutions to improve the quality of care and enable better outcomes for patients.
Enrique holds a Bachelor of Science in Telecommunications Management and served his country as a proud United States Marine.
Dr. Maroof Ahmed is a medical doctor who graduated from Imperial College London with dual degrees in Medicine and Business Management. He is the co-founder and COO of Digital Therapeutics.
Maroof spent 4 years conducting academic research in the fields of neurology, behavioural change, digital health and smoking cessation. He has published multiple peer-reviews papers on these topics and also acts as a reviewer for JMIR.
Whilst training to become a doctor, Maroof saw the impact smoking had on the lives of the patients around him and wanted to make a difference. So together with his co-founders, they put on hold their clinical careers to pursue Quit Genius full-time. This was a tough decision but they made this choice as it will allow them to make an impact on the lives of people worldwide at scale.
Matthias is a physician by training and holds a medical doctorate degree from the University of Ulm, Germany. He has gained both inpatient and outpatient medical expertise in various healthcare systems around the world. Matthias joined GAIA 20 years ago. In his current role as Chief Medical Solutions Officer, Matthias is responsible for leveraging GAIA’s decades of DTx medical research and expertise internationally and providing integrated solutions to payer and physician organizations.
With over 15 years of experience building startups, Rachel has led teams and strategy for recognized leaders in technology and media including CitySearch, Ticketmaster, and Current TV. Rachel earned her masters degree in Long-Term Strategic Planning in order to build profitable businesses that also did immense good. Rachel’s current favorite song in the SingFit catalog is “Walk the Line.”
An experienced entrepreneur and business leader, Ofer co-founded and built several digital media businesses, most recently iPlay/Oberon Media, a leading casual downloadable games company where he held several executive leadership roles. Ofer has also served as Co-Founder and President of Gate42 Technologies, a software startup in the customer relations management space. Earlier in his career, he served as an investment manager at an early stage seed fund and as a management consultant in the strategy practice of Trigger Consulting, a leading firm in Israel. Ofer holds an M.B.A. in Finance and a B.A. in Economics and Information Technologies, both from Tel Aviv University.
Mr. Bukstel has 25+ years of clinical data integration, data security, and communications experience. He
has successfully licensed systems and services to companies, including international pharmaceutical and
managed care organizations. Mr. Bukstel designed one of the first Electronic Medical Record Systems
that incorporated data communications standards and was a founding member of the ASTM E1238
Standard for Interoperability and Communication of Clinical Laboratory Data that became the
foundation of HL7. Mr. Bukstel designed the first client server (Novell Netware) Clinical Trials Protocol
Management System (Roche, Otsuka). He has been a national speaker on electronic data interchange
and has been a guest lecturer at The Wharton Business School and has lectured as an Adjunct Professor
at Thomas Jefferson University’s Center for Digital Health & Data Science. Mr. Bukstel has written
extensively on Blockchain and Healthcare and founded Clinical Blockchain in August 2016 to address
Patient – Doctor Messaging on a Blockchain Platform, speaking at Pfizer, Sanofi, GlaxoSmithKline, and
IEEE sponsored events nationally. Mr. Bukstel is currently the CEO for Giupedi , Inc., a development
stage Machine Learning Company focused on interoperability in the medical litigation marketplace.
Visa Honkanen MD, PhD, Chief Digital Officer, is responsible on the digital disruption and lean turn-around at the Helsinki University Hospital. His work focuses on digitalization, ehealth, and artificial intelligence development for the clinical use. His research interest has been in clinical studies and experimental statistics. Visa Honkanen is pediatric rheumatologist. He did his training at the Hospital for Sick Children, in Toronto. He still teaches and practices pediatric rheumatology.
Niklas founded two startup companies and is currently working at Fresenius Medical Care. He has more than 8 years’ experience in digital. Niklas blends entrepreneurial spirit, human-centered design and business acumen within the complex healthcare space. In his current role as the Director Digital Ecosystem at Fresenius Medical Care he is responsible for designing and evolving the digital ecosystem of FMC EMEA by aligning and creating new products and services in the Chronic Kidney Disease space. Moreover, he is currently performing an Executive MBA at the University of St. Gallen.
Sebastian Isaacs is the founder of Inflow – a digital health startup that helps people better manage their ADHD. Their mission is to help every person with ADHD reach their full potential by providing sustainable, accessible and cost-effective support. Prior to founding Inflow, Sebastian co-founded London Blockchain Labs – the largest blockchain community in the UK.
Dr. John Krakauer leads all scientific discovery and validation for MindMaze following the acquisition in 2018 of the medtech company he founded called Neuro Motor Innovations.
In addition to serving as Chief Medical Advisor for MindMaze, John is also:
-
John C. Malone Professor and Professor of Neurology, Neuroscience, and Physical Medicine and Rehabilitation at the Johns Hopkins University School of Medicine
-
Co-director of the Brain, Learning, Animation, and Movement (BLAM) Lab
Dr. Krakauer’s clinical interest is stroke, including ischemic cerebrovascular disease, subarachnoid and intracerebral hemorrhage, arteriovenous malformation, cerebral vasculitis, cerebral aneurysm, and venous and sinus thrombosis.
He received his bachelor’s and master’s degree from Cambridge University, and his medical degree from Columbia University College of Physicians and Surgeons where he was elected to Alpha Omega Alpha Medical Honor Society.
Digital Conference Platform
The Digital conference platform is purpose-built to enable us to provide you with a more personal experience.
For starters, no more wondering who is in the room! View and message the entire attendee list. If that’s not enough, there are a multitude of structured and unstructured networking opportunities to give you the chance to reconnect with old friends and meet your future collaborators.
Then there’s the learning. Through an engaging and interactive agenda, you will be able to actively or passively participate as much as you’d like. From polls and Q&A through to open discussions and dedicated roundtables, it has never been easier to accelerate your knowledge of Digital Therapeutics.
Imagine the possibilities of this digital event! Networking with your peers, learning from the experts, collaborating, and shaping the future of Digital Therapeutics – all on a world-class, purpose-built platform.
Partner With Us
PARTNERSHIPS
The DTx summits are the premier events for senior executives from DTx companies, Pharma, Investors, HCPs and Payers.
DTx Europe 2021 is the eighth summit in the DTx series. We are expecting 200 people online at the virtual Summit, which is what our attendees and partners tell us is the optimum size
We believe that getting the right mix of partners is critical for a successful summit for you and our attendees. The DTx summit provides a rare opportunity to showcase your business to a world-class audience.
You will be impressed with our service and truthfulness. We will be honest with you throughout the process from deciding which option is right for you to delivery on-site.
Get in touch today to learn more and avoid missing out!
Register for the Event
For pricing and booking options please click the button to go to the registration page.